The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Exploiting evolutionary principles to prolong tumor control in preclinical models of breast cancer
Open accessAbstract
Using evolutionary principles to guide drug administration, monotherapy with paclitaxel can maintain prolonged stability of breast cancer in preclinical models.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Multidrug resistance in cancer: role of ATP–dependent transporters
Gottesman, M. M., Fojo, T., & Bates, S. E. (2002) · Nature Reviews Cancer · doi:10.1038/nrc706 · Cited by 5,536
Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
Jain, R. K. (2005) · Science · doi:10.1126/science.1104819 · Cited by 5,527
Greaves, M., & Maley, C. C. (2012) · Nature · doi:10.1038/nature10762 · Cited by 3,162
Gatenby, R. A., Silva, A. S., Gillies, R. J., & Frieden, B. R. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3658 · Cited by 846
Self-citationA microenvironmental model of carcinogenesis
Gatenby, R. A., & Gillies, R. J. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2255 · Cited by 721
Self-citation(2016) · ecancermedicalscience · doi:10.3332/ecancer.2014.463 · Cited by 676
How Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicine
Gerlinger, M., & Swanton, C. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605912 · Cited by 421
A change of strategy in the war on cancer
Gatenby, R. A. (2009) · Nature · doi:10.1038/459508a · Cited by 402
Self-citationVascular normalization as a therapeutic strategy for malignant and nonmalignant disease.
Goel, S., Wong, A. H.-K., & Jain, R. K. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006486 · Cited by 352
McDermott, M., Eustace, A. J., Busschots, S., Breen, L., Crown, J., Clynes, M., O’Donovan, N., & Stordal, B. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00040 · Cited by 315
Shen, F., Chu, S., Bence, A. K., Bailey, B., Xue, X., Erickson, P. A., Montrose, M. H., Beck, W. T., & Erickson, L. C. (2008) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.127704 · Cited by 263
Chemotherapy for breast cancer (Review)
Hassan (2010) · Oncology Reports · doi:10.3892/or_00000963 · Cited by 197
Exploiting Evolution To Treat Drug Resistance: Combination Therapy and the Double Bind
Basanta, D., Gatenby, R. A., & Anderson, A. R. A. (2011) · Molecular Pharmaceutics · doi:10.1021/mp200458e · Cited by 163
Self-citationEvolutionary Approaches to Prolong Progression-Free Survival in Breast Cancer
Silva, A. S., Kam, Y., Khin, Z. P., Minton, S. E., Gillies, R. J., & Gatenby, R. A. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-2235 · Cited by 148
Self-citationClonal variation of MCF-7 breast cancer cells in vitro and in athymic nude mice.
Seibert, K., Shafie, S. M., Triche, T. J., Whang‐Peng, J., O’Brien, S. J., TONEY, J. H., Huff, K. K., & Lippman, M. E. (1983) · PubMed · Cited by 127
Frei, E., ELIAS, A. D., Wheeler, C., Richardson, P. G. G., & Hryniuk, W. M. (1998) · PubMed · Cited by 115
Induction by verapamil of a rapid increase in ATP consumption in multidrug‐resistant tumor cells
Broxterman, H. J., Pinedo, H. M., Kuiper, C. M., Kaptein, L. C. M., Schuurhuis, G. J., & Lankelma, J. (1988) · The FASEB Journal · doi:10.1096/fasebj.2.7.3350243 · Cited by 111
Gatenby, R. A., Cunningham, J. J., & Brown, J. S. (2014) · Nature Communications · doi:10.1038/ncomms6499 · Cited by 86
Self-citationGyőrffy, B., Serra, V., Jürchott, K., Abdul‐Ghani, R., Garber, M., Stein, U., Petersen, I., Lage, H., Dietel, M., & Schäfer, R. (2005) · Oncogene · doi:10.1038/sj.onc.1208908 · Cited by 79
Minimization of thermodynamic costs in cancer cell invasion
Liu, L., Duclos, G., Sun, B., Lee, J., Wu, A. Y., Kam, Y., Sontag, E. D., Stone, H. A., Sturm, J. C., Gatenby, R. A., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1221147110 · Cited by 65
Self-citationTegze, B., Szállási, Z., Haltrich, I., Pénzváltó, Z., Tóth, Z., Likó, I., & Győrffy, B. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030804 · Cited by 59
Metronomic therapy and breast cancer: A systematic review
Montagna, E., Cancello, G., Dellapasqua, S., Munzone, E., & Colleoni, M. A. (2014) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2014.06.002 · Cited by 51
A unifying theory of carcinogenesis, and why targeted therapy doesn’t work
Gillies, R. J., Flowers, C. I., Drukteinis, J. S., & Gatenby, R. A. (2012) · European Journal of Radiology · doi:10.1016/s0720-048x(12)70018-9 · Cited by 32
Self-citationUeda, S., Kuji, I., Shigekawa, T., Takeuchi, H., Sano, H., Hirokawa, E., Shimada, H., Suzuki, H., Oda, M., Osaki, A., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0098715 · Cited by 22
Kam, Y., Das, T., Minton, S. E., & Gatenby, R. A. (2014) · Women s Health · doi:10.2217/whe.14.23 · Cited by 20
Self-citationMehta, R. S., Jackson, D., & Schubbert, T. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.9377 · Cited by 8
Cited by
Clonal heterogeneity and tumor evolution: past, present, and the future
McGranahan, N., & Swanton, C. (2017) · Cell · doi:10.1016/j.cell.2017.01.018 · Cited by 2,840
“In contrast to standard clinical practice where the goals of therapy are to reduce tumor burden, the focus of adaptive therapy is to maximize time to progression by stabilizing tumor size (Enriquez-Navas et al., 2016; Gatenby et al., 2009).”
From tumour heterogeneity to advances in precision treatment of colorectal cancer
Punt, C. J. A., Koopman, M., & Vermeulen, L. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.171 · Cited by 654
Integrating evolutionary dynamics into treatment of metastatic castrate-resistant prostate cancer
Zhang, J., Cunningham, J. J., Brown, J. S., & Gatenby, R. A. (2017) · Nature Communications · doi:10.1038/s41467-017-01968-5 · Cited by 556
Self-citationSignaling pathways involved in colorectal cancer: pathogenesis and targeted therapy
Li, Q., Geng, S., Luo, H., Wang, W., Mo, Y.-Q., Luo, Q., Wang, L., Song, G.-B., Sheng, J.-P., & Xu, B. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01953-7 · Cited by 546
A framework for designing delivery systems
Poon, W., Kingston, B. R., Ouyang, B., Ngo, W., & Chan, W. C. W. (2020) · Nature Nanotechnology · doi:10.1038/s41565-020-0759-5 · Cited by 524
Metadata
- Authors
- Enriquez-Navas, P. M., Kam, Y., Das, T., Hassan, S., Silva, A., Foroutan, P., Ruiz, E., Martinez, G., Minton, S., Gillies, R. J., & Gatenby, R. A.
- Venue
- Science Translational Medicine
- Published
- 2016-02-24
- Volume
- 8
- Issue
- 327
- Pages
- 327ra24-327ra24
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- OpenAlex
- W2277895489
- Cited by
- 322
- References
- 26
- FWCI
- 35.98
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.